MAPT and Alzheimer disease: Also, it is observed that the U1 snRNP deposition with NFT in postmortem brains of AD patients (Bai et al., 2013; Hales et al., 2014), MAPT transgenic mice (Vanderweyde et al., 2016; Maziuk et al., 2018), and in laboratory conditions (Bishof et al., 2018).